Loading...
XTSXKNE
Market cap9mUSD
Dec 24, Last price  
0.10CAD
1D
5.26%
1Q
-25.93%
Jan 2017
-33.33%
Name

Kane Biotech Inc

Chart & Performance

D1W1MN
XTSX:KNE chart
P/E
P/S
92.30
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
9.67%
Rev. gr., 5y
-21.70%
Revenues
149k
-94.42%
13,414024,09817,15600000159,94541,899104,624244,7561,035,302506,2731,693,5241,341,5741,607,7752,668,352148,980
Net income
-5m
L+29.41%
-602,562-1,009,650-955,759-1,089,955-1,076,844-877,247-973,254-1,221,149-1,459,495-1,447,365-1,614,908-1,709,997-2,548,748-2,786,174-3,260,999-960,178-3,716,686-4,604,566-3,889,892-5,034,103
CFO
-3m
L+5.85%
-503,499-808,870-843,129-798,377-1,073,400-764,261-792,058-940,305-1,155,293-1,166,443-1,049,161-1,388,494-2,363,319-2,044,247-2,853,997-955,372-3,938,970-2,289,190-3,043,472-3,221,626
Earnings
Mar 24, 2025

Profile

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
IPO date
May 07, 2003
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
149
-94.42%
2,668
65.97%
1,608
19.84%
Cost of revenue
3,739
6,032
6,491
Unusual Expense (Income)
NOPBT
(3,590)
(3,364)
(4,884)
NOPBT Margin
Operating Taxes
1,143
495
Tax Rate
NOPAT
(3,590)
(4,507)
(5,378)
Net income
(5,034)
29.41%
(3,890)
-15.52%
(4,605)
23.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
416
974
1,116
BB yield
-4.09%
-8.96%
-6.19%
Debt
Debt current
7,084
4,278
2,512
Long-term debt
3,159
3,666
3,424
Deferred revenue
191
837
777
Other long-term liabilities
829
Net debt
9,493
6,395
3,793
Cash flow
Cash from operating activities
(3,222)
(3,043)
(2,289)
CAPEX
(9)
(88)
(354)
Cash from investing activities
(116)
(108)
(374)
Cash from financing activities
2,982
3,103
2,808
FCF
(3,316)
(4,323)
(6,285)
Balance
Cash
749
1,105
1,153
Long term investments
444
989
Excess cash
742
1,416
2,062
Stockholders' equity
(16,158)
(11,582)
(7,073)
Invested Capital
18,029
15,139
10,998
ROIC
ROCE
EV
Common stock shares outstanding
127,120
120,702
112,600
Price
0.08
-11.11%
0.09
-43.75%
0.16
14.29%
Market cap
10,170
-6.38%
10,863
-39.70%
18,016
19.65%
EV
21,812
19,643
24,128
EBITDA
(3,352)
(3,100)
(4,696)
EV/EBITDA
Interest
1,215
822
416
Interest/NOPBT